Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Clinical Trial of Hydroxyflutamide (Liproca Depot) in Prostate Cancer

Trial Profile

A Phase III Clinical Trial of Hydroxyflutamide (Liproca Depot) in Prostate Cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxyflutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2019 According to a LIDDS media release, this phase III clinical trial will be conducted in urology clinics in China and will be fully financed by the Jiangxi Puheng Pharma.
    • 07 Nov 2019 According to a LIDDS media release, LIDDS AB, Jiangxi Puheng Pharma has after reviewing the preliminary results in LPC-004 decided to move ahead and has initiated discussions with Chinese medical authority, CFDA. This phase III study protocol will be developed in close collaboration with LIDDS.
    • 06 Mar 2019 According to the LIDDS media release, this study will be fully funded by the Chinese licensee.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top